877149-16-1

Upstream product

• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 877149-10-5 methyl 4-bromo-2-chloro-6-methylbenzoate 

Relevant academic research and scientific papers

CYCLIC AMINE DERIVATIVE AND MEDICAL USE THEREOF

A cyclic amine derivative represented by general Formula (I): wherein R1 represents an alkyl group having 1 to 3 carbon atoms; A represents a group represented by general Formula (II-1), (II-2), or (II-3): R2 represents a hydrogen at

HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS

This application relates to compounds of the following Formula: or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegen

SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS

This application relates to compounds of Formula (IIu) as well as specific compounds thereof wherein a pyrazole or triazole is present instead of the imidazole drawn above and pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-y which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, A6, A7, W1, R1, R2, R3, R4, R5a, R5b, R6, R7, R7a, R7b, R8, R8a, R8b, R9, R9a, R9b and R10 and subscripts “m” and “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS

The present invention is directed to compounds of formula (I), wherein R1 is a ring and n is a number from 1 to 8. The invention also relates to use of the compounds in therapy as metabotropic glutamate receptor modulators, particularly in neurological and psychiatric disorders.